RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype
Open Access
- 22 January 2015
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 169 (3) , 344-351
Abstract
Summary: Correlative and functional studies support the involvement of the RUNX gene family in haematological malignancies. To elucidate the role of epigenetics in RUNX inactivation, we evaluated promoter DNA methylation of RUNX1, 2, and 3 in 23 leukaemia cell lines and samples from acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) and myelodysplatic syndromes (MDS) patients. RUNX1 and RUNX2 gene promoters were mostly unmethylated in cell lines and clinical samples. Hypermethylation of RUNX3 was frequent among cell lines (74%) and highly variable among patient samples, with clear association to cytogenetic status. High frequency of RUNX3 hypermethylation (85% of the 20 studied cases) was found in AML patients with inv(16)(p13.1q22) compared to other AML subtypes (31% of the other 49 cases). RUNX3 hypermethylation was also frequent in ALL (100% of the six cases) but low in MDS (21%). In support of a functional role, hypermethylation of RUNX3 was correlated with low levels of protein, and treatment of cell lines with the DNA demethylating agent, decitabine, resulted in mRNA re‐expression. Furthermore, relapse‐free survival of non‐inv(16)(p13.1q22) AML patients without RUNX3 methylation was significantly better (P = 0·016) than that of methylated cases. These results suggest that RUNX3 silencing is an important event in inv(16)(p13.1q22) leukaemias.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP100202)
- National Institutes of Health (CA153114)
- National Institutes of Health (CA016672)
- Edward P. Evans Foundation
- Fundación Ramón Areces
This publication has 28 references indexed in Scilit:
- DNA methylation as an epigenetic biomarker in colorectal cancerOncology Letters, 2013
- Association between RUNX3 promoter methylation and gastric cancer: a meta-analysisBMC Gastroenterology, 2011
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Downregulation of RUNX1 by RUNX3 Requires the RUNX3 VWRPY Sequence and Is Essential for Epstein-Barr Virus-Driven B-Cell ProliferationJournal of Virology, 2009
- Lack of CpG Island Methylator Phenotype Defines a Clinical Subtype of T-Cell Acute Lymphoblastic Leukemia Associated With Good PrognosisJournal of Clinical Oncology, 2005
- Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemiaLeukemia, 2005
- Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomesBlood, 2004
- Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemiaLeukemia, 2003
- Genome‐wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation‐mediated fusion eventsGenes, Chromosomes and Cancer, 2003
- AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver HematopoiesisCell, 1996